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von Hippel–Lindau disease (VHL) is a familial neoplasia syndrome associated with 
multisystem tumor development. Depending on tumor type and location, current treat-
ments for VHL-associated tumors can include a combination of chemotherapy, radiation 
therapy, and/or surgery. Central nervous system (CNS) manifestations of VHL include 
craniospinal hemangioblastomas and endolymphatic sac tumors (ELSTs). While the first-
line treatment for both types of VHL-associated CNS tumors is surgery, the indications 
for treatment are patient specific and different for each tumor type. Although early sign/
symptom formation is the primary indication for resection of craniospinal hemangioblas-
tomas, radiographic discovery (asymptomatic and symptomatic) of ELSTs can be an 
indication for resection of ELSTs in VHL patients. Recently, research has revealed that 
specific VHL germline mutations may permit targeted medical treatments of not only 
CNS manifestations of VHL-associated tumors but also visceral tumors. Specifically, 
missense mutations can result in the translation of functional VHL protein (pVHL) that is 
rapidly degraded resulting in functional loss of the pVHL, and inhibitors of pVHL degra-
dation may slow protein degradation and restore pVHL function. Emerging research will 
investigate the safety and practicality of using potential targeted therapies.
Keywords: von Hippel–Lindau, personalized medicine, hemangioblastoma, histone deacetylase inhibitor, 
endolymphatic sac tumor
iNTRODUCTiON
von Hippel–Lindau disease (VHL) is an autosomal dominant inherited genetic disorder caused 
by a germline mutation of chromosome 3 (VHL gene). Patients affected with VHL develop multiple 
central nervous system (CNS) lesions, including retinal and craniospinal hemangioblastomas, as 
well as endolymphatic sac tumors (ELSTs). Visceral VHL-associated lesions frequently include 
renal cell carcinomas, renal cysts, pheochromocytomas, extra-adrenal paragangliomas, pancre-
atic microcystic adenomas, pancreatic cysts, and pancreatic neuroendocrine tumors, as well as 
cystadenomas of the epididymis and broad ligament (1–3) (Figure  1). VHL has an incidence 
of approximately 1 in 36,000–39,000 live births (4, 5). Penetrance is nearly complete and most 
(over 90%) patients display evidence of the disease by the age of 65 years (6).
Treatment of VHL is complex due to the multisystem involvement, the location of tumors, and 
the immense variability of symptoms that can be produced related to various tumor locations 
and systems involved. Recent studies have elucidated new germline-based targets for treatment. 
Existing treatments include combinations of chemotherapy, radiation therapy, and surgical resec-
tion. We describe the current personalized management of the CNS manifestations of VHL and 
FiGURe 1 | Central nervous system and systemic locations and types 
of tumors of patients harboring germline protein vHL mutations and 
von Hippel–Lindau disease [adapted from Lonser et al. (7)].
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the potential putative therapeutics that are based on germline 
mutation types.
GeNeTiCS AND PATHOGeNeSiS
Mutations in the VHL gene lead to the development of the mani-
festations of VHL. The VHL gene is located on the short arm of 
chromosome 3 (3p) and is a tumor suppressor gene (8). Germline 
mutations of VHL account for more than 95% of the patients 
affected by VHL (5% have somatic inactivation of the VHL gene 
in sporadically occurring hemangioblastomas and renal cell 
carcinomas) (9). VHL patients inherit a VHL germline mutation 
from the VHL-affected parent and a normal (wild-type) gene 
from the non-affected parent. Tumorigenesis occurs when the 
wild-type VHL allele is inactivated (loss of heterozygosity) in 
certain susceptible target organs that include the viscera (kid-
neys, pancreas, adrenal glands, and adnexal organs), as well as 
the CNS (7).
The VHL gene encodes VHL protein (pVHL), a protein that is 
part of the E3 ubiquitin ligase, which is involved in proteasomal 
degradation. It targets hypoxia inducible factor (HIF)-1/2α (10) 
transcription factors that are activated in hypoxic conditions to 
upregulate genes, including vascular endothelial growth factor 
(VEGF), transcription growth factor (TGF), erythropoietin 
(EPO), EPO receptor, transferrin, and angiopoietin (11). These 
factors are involved in angiogenesis, erythropoiesis, cell prolif-
eration, and/or tumorigenesis/metastasis. HIF-2α is a known 
oncogene that contributes to cell proliferation and tumorigenesis 
(11). pVHL participates in degradation of HIF-1/2-α by binding 
the transcription factors to the proteasome complex (Figure 2). 
When the VHL gene is mutated and its function is reduced/lost, 
HIF-1/2α is upregulated (even in the absence of hypoxic condi-
tions) due to its reduced degradation by the VHL ubiquitin– 
proteasome complex (7).
Multiple VHL germline mutations have been discovered, 
ranging from deletions to missense mutations. Germline VHL 
missense mutations are the most common and underlie 60–70% 
of all VHL-associated mutations (4). Recent studies have shown 
that the proteins translated from the missense mutated VHL gene 
are highly unstable and rapidly degraded (10), but retain the 
functional capacity of wild-type protein. Consequently, treatment 
strategies that extend the half-life of pVHL in this circumstance 
could lead to normalization (reversal) of VHL-related pathobio-
logic features.
vHL-ASSOCiATeD TUMORS
Hemangioblastomas
Hemangioblastomas are highly vascular tumors that arise in the 
CNS. They are the most common tumor presentation of VHL 
patients. Previously, studies have estimated that 60–90% of VHL 
patients will develop multiple hemangioblastomas in their life-
time (12, 13). Cerebellar lesions are the most common, followed 
by spinal cord, brainstem, and supratentorial tumors (Figure 3) 
(3, 9). CNS hemangioblastomas are histologically benign but 
cause a multitude of symptoms and can result in death depending 
on their location and size. Symptomatic CNS hemangioblastomas 
are most frequently associated with peritumoral cysts, although 
symptoms can be caused by solid tumors and are location 
dependent (1, 14, 15).
Recent natural history studies have provided a better under-
standing of the growth and development of hemangioblastomas 
in VHL. We prospectively studied 250 VHL disease patients 
with a total of 1921 CNS hemangioblastomas (9). At the end 
of the study, mean number of craniospinal hemangioblastomas 
had increased from 7 to 8 per person over a mean follow up of 
6.9  years (new hemangioblastoma development was inversely 
associated with age). When observed out to 5 years, 49% of known 
hemangioblastomas progressed in size in a linear, saltatory, or 
exponential pattern. Brainstem and cerebellar hemangioblas-
tomas grew significantly faster than the spinal or cauda equina 
hemangioblastomas. Male sex was associated with a significantly 
faster growth rate than females. Most VHL patients will develop 
multiple hemangioblastomas over time. Because hemangioblas-
tomas grow at different rates, in multiple locations, and exhibit 
irregular growth patterns, symptom formation can be unpredict-
able. Surgical resection is often reserved until the first onset of 
signs/symptoms that correlate with the location of the heman-
gioblastoma. This management paradigm attempts to ensure 
that unnecessary surgical intervention and associated possible 
complications are avoided. This can often result in maintenance 
of baseline neurologic function for most patients (9).
Peritumoral cysts are a frequent cause of hemangioblastoma-
associated signs/symptoms, and they form by a plasma ultrafiltrate 
FiGURe 3 | Radiographic images of hemangioblastomas. (A) Axial, contrasted, T1-weighted MRI showing cerebellar hemangiolastoma with contrast 
enhancing mural nodule and peritumoral cyst. (B) Sagittal, contrasted, T1-weighted MRI revealing contrast enhancing medullary hemangioblastoma with 
surrounding vasogenic edema. (C) Sagittal, contrasted, T1-weighted MRI with contrast enhancing posterior/dorsal hemangioblastoma with associated syrinx 
[adapted from Lonser et al. (7)].
FiGURe 2 | Function of protein vHL in the proteasome. pVHL is thought to function as an E3 ubiquitin ligase in the proteasome complex and bind HIF-1α, 
which results in ubiquitination of HIF-1α and leads to degradation. In normoxic conditions, HIF-1α is degraded, but in conditions of hypoxia, HIF-1α is upregulated. 
In the absence of pVHL, HIF-1α is not ubiquitinated and degraded [adapted from Lonser et al. (7)].
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passing into tissue surrounding the hemangioblastoma from 
permeable tumor blood vessels (1). Previously, we prospectively 
followed 225 patients with VHL disease, of which 132 patients 
had 292 peritumoral cysts (14). Approximately 75% of peritu-
moral cysts progressed within 3 years. Cysts grew faster if located 
in the cerebellum, in patients under 35 years of age, and if they 
were associated with symptoms. Peritumoral cysts appeared to 
grow in three patterns, including saltatory (phases of growth 
followed by stability), linear, or exponential. Overall, a majority 
of the cysts grew in a saltatory manner (41.7%). However, of the 
60 symptomatic peritumoral cysts, 45% grew exponentially (9). 
Risk of an increased total number of tumors was significantly 
associated with a partial deletion germline mutation and male 
sex, while new cyst development was associated with a greater 
number of cysts at the time of initial evaluation for the study 
and age younger than 35 years.
Radiation therapy [most frequently stereotactic radiosurgery 
(SRS)] has been utilized for treatment of CNS hemangioblastomas 
in VHL. Asthagiri and colleagues (16) prospectively evaluated 
the effect of SRS on craniospinal hemangioblastomas in 20 VHL 
patients (11 symptomatic, 9 asymptomatic) with 44 hemangio-
blastomas. Fourteen tumors (32%) progressed after SRS treat-
ment, and four of these tumors required surgical resection. Local 
control rates decreased over time with 91, 83, 70, 61, and 51% at 
2, 5, 8, 10, and 15 years, respectively, and were similar to rates 
of progression in untreated hemangioblastomas (9). These data 
indicate that SRS should be reserved for treating hemangioblas-
tomas that are not surgically resectable or in patients who cannot 
tolerate surgical resection (16).
eNDOLYMPHATiC SAC TUMORS
Endolymphatic sac tumors are vascular, low-grade papillary 
adenocarcinomas affecting up to 11% of VHL patients. Mean 
age of diagnosis is 22  years, and bilateral ELSTs are found in 
approximately 30% of patients with VHL (17). The majority of 
4Schunemann et al. Personalized Medicine in VHL
Frontiers in Surgery | www.frontiersin.org June 2016 | Volume 3 | Article 39
the patients had associated audiovestibular symptoms, including 
sensorineural hearing loss (84% of ears), tinnitus (73%), and 
vertigo (68%) that did not correlate with tumor size (18). The 
audiovestibular findings associated with ELSTs are thought to be 
due to intralabyrinthine hemorrhage, endolymphatic hydrops, 
and/or direct invasion of the otic capsule by tumor (19). Sudden 
hearing loss (43%) has been correlated with intralabyrinthine 
hemorrhage. Gradual hearing loss (47%) is most often related to 
endolymphatic hydrops.
Regular screening of VHL patients for ELSTs is recommended, 
with surgical intervention in selected patients before morbidity 
develops. Surgery is curative for completely excised tumors. Kim 
and colleagues found that hearing was stabilized postoperatively 
in 90% of patients after ELST resection (18). Current indications 
for ELST resection in VHL patients include imaging evidence of 
an ELST with serviceable hearing (and/or audiovestibular signs/
symptoms), evidence of ELST-associated intralabyrinthine hem-
orrhage, ELST-associated hydrops, or mass effect by the ELST 
(19, 20). Contrast-enhanced delayed FLAIR MRI has been found 
to be an efficacious, non-invasive method of detecting ELST-
associated hydrops (21). The role of adjuvant therapy, including 
chemotherapy, fractionated radiotherapy, or stereotactic radio-
surgery, is not established.
eMeRGiNG TARGeTS FOR 
TReATMeNT OF vHL
Recent investigations into the pathogenesis of VHL tumors 
have revealed new potential targets for treatment. Metelo and 
colleagues (22) studied VHL models in zebrafish using vhl−/− 
embryos. Treatment with HIF-2α inhibitors decreased expression 
of HIF-2α targeted genes. The effect was dose dependent in these 
studies. It improved new angiogenic sprouting that was seen 
in vhl−/− embryos and returned abnormal cardiac function to 
baseline, suggesting that HIF-2α could lead to potential targeted 
treatments for systemic VHL tumors.
The most frequent mutations in VHL are missense mutations. 
VHL patients that harbor a missense germline mutation have a 
quantitative reduction of missense mutant VHL protein (pVHL), 
but still maintain physiologic pVHL mRNA expression. Recent 
data indicate that mutant pVHL is highly unstable and is quickly 
degraded after translation. Interestingly, missense mutant pVHL 
retains its E3 ligase function, including HIF degradation. The 
premature pVHL degradation is due to misfolding and imbalance 
of chaperonin binding (23).
Histone deacetylase inhibitors (HDACis) can modulate the 
pVHL degradation pathway by inhibiting the HDAC6–Hsp90 
chaperone axis, stabilizing pVHL, and restoring activity compa-
rable to wild-type protein in  vitro and in mouse VHL models. 
HDACi-mediated stabilization of missense pVHL significantly 
attenuates the growth of mouse VHL tumors (23). These findings 
provide direct insight into the pathobiology of VHL-associated 
tumors and elucidate a new treatment paradigm for personalized 
therapy in those individuals with missense VHL mutations.
PeRSONALiZeD APPROACHeS
von Hippel–Lindau disease is a complex and progressive process 
involving multisystem tumor formation. Individuals afflicted 
with VHL disease require a personalized approach for therapy, 
as tumors are neither uniform in their locations nor identical in 
their symptomatology. Currently, successful systemic treatments 
are lacking. The first choice of therapy for hemangioblastomas 
and ELSTs is surgery, and the decision to proceed with surgery 
is personalized to the individual. Surgery is reserved for heman-
gioblastomas based on symptom development and progression 
in tumor or cyst size. Surgery for ELSTs can also be based upon 
symptomatology, but indications also include radiographic find-
ings of ELSTs and serviceable hearing. Care is taken to tailor 
the exact treatment to each individual patient and their tumor 
burden.
Recent studies revealed missense mutations in the VHL gene 
actually allow for transcription of the protein, albeit an unstable 
one that is rapidly degraded due to misfolding and chaperonin 
binding. The protein is then unable to function and degrade its 
target, HIF-2α as part of the proteasome. HDACis interfere with 
chaperonin pathways and, in result, stabilize the protein and 
allow return to function in vitro and in VHL mouse models. This 
offers a unique opportunity for a new treatment modality that 
in theory would be able to treat the underlying mechanism of 
tumorigenesis and affect the whole body, multiple systems, and 
possibly all of the differing tumor types in the body.
Further investigation and Phase I clinical trials would need 
to be conducted to assess the feasibility of developing HDACis 
as possible treatments. Currently, vorinostat, an HDACi, is 
undergoing Phase I trials for VHL patients with hemangioblas-
tomas and missense mutations, trial #NCT02108002. With the 
potential of new therapies on the horizon, this could permit 
further treatment of the complex manifestations of VHL dis-
ease tailored to the individuals with this most common VHL 
germline mutation.
CONCLUSiON
von Hippel–Lindau disease is a complex disorder, and patients 
develop a wide constellation of symptoms related to the vary-
ing locations and types of tumors present. Currently, therapies 
are tailored toward the individual tumors and patient findings. 
Discovery of pVHL stabilization with use of HDACis in mis-
sense mutated pVHL provides a potential for new treatment 
directed toward the underlying mechanisms of tumorigenesis 
that could further tailor therapy toward the individual with VHL 
and offer a uniform treatment for various tumors associated with 
the disease.
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